The safety and efficacy of BTK inhibitor ibrutinib is examined for the treatment of relapsed/refractory mantle cell lymphoma.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
![](https://i.ytimg.com/vi/dsMBSaWFKgQ/maxresdefault.jpg)
The safety and efficacy of BTK inhibitor ibrutinib is examined for the treatment of relapsed/refractory mantle cell lymphoma.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]